{"id":"NCT03777176","sponsor":"Zealand Pharma","briefTitle":"A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism","officialTitle":"A Two-Period, Open-label Trial Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children With Congenital Hyperinsulinism","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-02-07","primaryCompletion":"2020-08-31","completion":"2020-10-05","firstPosted":"2018-12-17","resultsPosted":"2023-12-13","lastUpdate":"2023-12-13"},"enrollment":32,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Congenital Hyperinsulinism"],"interventions":[{"type":"DRUG","name":"Dasiglucagon","otherNames":["ZP4207"]},{"type":"OTHER","name":"Standard of Care","otherNames":[]}],"arms":[{"label":"Standard of Care + dasiglucagon","type":"EXPERIMENTAL"},{"label":"Standard of Care Only","type":"OTHER"}],"summary":"The objective of the trial is to evaluate the efficacy and safety of dasiglucagon administered as a subcutaneous (SC) infusion in reducing hypoglycemia in children with CHI.","primaryOutcome":{"measure":"Hypoglycemia Episode Rate","timeFrame":"Baseline, Week 2-4 (Treatment Period 1)","effectByArm":[{"arm":"Standard of Care + Dasiglucagon","deltaMin":5.29,"sd":5.256},{"arm":"Standard of Care Only","deltaMin":5.85,"sd":2.767}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5028"}]},"eligibility":{"minAge":"3 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":13},"locations":{"siteCount":10,"countries":["United States","Germany","Israel","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":16},"commonTop":["Vomiting","Eczema","Rash","Upper Respiratory Tract Infection","Hyperglycaemia"]}}